{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:59:05Z","timestamp":1765886345895,"version":"3.41.2"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Previous studies demonstrated equivalence in terms of efficacy and safety of biosimilars (bsDMARDs) compared to original treatments (boDMARDs) and in switching situations. Less is known about what happens when initiating a bsDMARD in a molecule na\u00efve patient. The objectives of our study were to compare the retention of treatment of subcutaneous boDMARDs and bsDMARDs globally, depending on the disease [rheumatoid arthritis (RA), spondyloarthritis (SpA), or psoriatic arthritis (PsA)], molecule [etanercept (ETN) or adalimumab (ADA)], line of treatment, or presence of citrate in the context of first use of each molecule (namely initiation) and to analyze treatment retention\u2019s predictive factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>This multicenter retrospective study used data from shared medical records of the RIC-FRANCE network, encompassing the prescription of hospital rheumatologists and attached practitioners, of patients with RA, SpA, or PsA, with the starting ETN between 03\/10\/2016 and 31\/07\/2020, or ADA between 23\/10\/2018 and 31\/07\/2020. Clinical data were collected from medical records. Retention analysis was performed using Kaplan\u2013Meier curves and the log-rank test. Retention\u2019s predictive factors were analyzed using Cox proportional-hazard ratio.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eight hundred forty-five prescriptions were analyzed: 340 boDMARDs and 505 bsDMARDs. About 57% of prescriptions concerned women. The mean age was 51.8 years. About 38% were prescriptions for RA, 16% for PsA, and 46% for SpA. An increase in the initiation over time was observed for both ETN and ADA. The retention rate of bsDMARDs was superior to boDMARDs\u2019 one (39 vs. 23 months; <jats:italic>p<\/jats:italic> = 0.045). When molecules are compared, the difference was significant only for ETN (45 vs. 19 months for boDMARD; <jats:italic>p<\/jats:italic> = 0.0265). When comparing diseases, the difference in favor of bsDMARDs was significant in patients with RA only (<jats:italic>p<\/jats:italic> = 0.041). Citrated treatments displayed better retention compared to citrate-free treatments (<jats:italic>p<\/jats:italic> = 0.0137). Multivariable analysis of predictive factors for the cessation of treatment found shorter disease duration, boDMARD prescription, hospital practitioner prescription, late line of treatment, and female sex as significant. More side effects were observed with boDMARDs, especially more infections (17.8% vs. 7.8%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Even if bsDMARDs\u2019 prescription increases over time, its penetration rate is still below expectations. bsDMARDs displayed better retention compared to boDMARDs, especially for ETN, and in patients with RA. Citrated treatments had better retention. Prescription by a full-time hospital-based rheumatologist is associated with poorer retention.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.989514","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T12:37:00Z","timestamp":1665059820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study"],"prefix":"10.3389","volume":"9","author":[{"given":"Guillaume","family":"Larid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Baudens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Dandurand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Coquerelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Goeb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie H\u00e9l\u00e8ne","family":"Guyot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Marguerie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Maury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Veillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Houvenagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Hugues","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9-Marc","family":"Flipo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.rdc.2015.07.010","article-title":"Biologic therapy for psoriatic arthritis.","volume":"41","author":"Mease","year":"2015","journal-title":"Rheum Dis Clin N Am."},{"key":"B2","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.","volume":"69","author":"Nam","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B3","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2014-205322","article-title":"Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.","volume":"74","author":"Callhoff","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jbspin.2014.03.019","article-title":"Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies.","volume":"81","author":"Casta\u00f1eda-Hern\u00e1ndez","year":"2014","journal-title":"Joint Bone Spine."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00288","article-title":"Pricing and reimbursement of biosimilars in Central and Eastern European countries.","volume":"8","author":"Kawalec","year":"2017","journal-title":"Front Pharmacol."},{"journal-title":"Biosimilar Medicines.","year":"2019","key":"B9"},{"journal-title":"Fast facts?: Biosimilars.","year":"2018","author":"Cornes","key":"B10"},{"key":"B11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/rheumatology\/kew206","article-title":"Biosimilars in rheumatology: understanding the rigor of their development.","volume":"56","author":"Goel","year":"2017","journal-title":"Rheumatology."},{"key":"B12","article-title":"Biosimilar cost savings in the United States: initial experience and future potential.","volume":"7","author":"Mulcahy","year":"2018","journal-title":"Rand Health Q."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/cpt.2322","article-title":"Cost to medicare of delayed adalimumab biosimilar availability.","volume":"110","author":"Lee","year":"2021","journal-title":"Clin Pharmacol Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.therap.2021.10.012","article-title":"Penetration rate of anti-TNF biosimilars and savings at 5 years after their introduction in French hospitals.","volume":"77","author":"Jarrion","year":"2021","journal-title":"Therapies."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001079","article-title":"Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: nordic collaborative observational study of 2334 biologics na\u00efve patients with spondyloarthritis.","volume":"5","author":"Lindstr\u00f6m","year":"2019","journal-title":"RMD Open."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1093\/rheumatology\/keab933","article-title":"Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden","volume":"61","author":"Di Giuseppe","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89790-4","article-title":"Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator.","volume":"11","author":"Cingolani","year":"2021","journal-title":"Sci Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40259-019-00393-y","article-title":"Retention rate and safety of biosimilar CT-P13 in rheumatoid arthritis: data from the korean college of rheumatology biologics registry.","volume":"34","author":"Kim","year":"2020","journal-title":"BioDrugs."},{"key":"B19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br J Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jbspin.2018.12.003","article-title":"Repeated switches between reference product etanercept and biosimilar do not affect disease activity or retention rate of etanercept over 24 months \u2013 a cohort study with historical controls.","volume":"86","author":"Sigurdardottir","year":"2019","journal-title":"Joint Bone Spine."},{"key":"B21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1136\/annrheumdis-2018-213474","article-title":"To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.","volume":"78","author":"Glintborg","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","article-title":"A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.","volume":"76","author":"Glintborg","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.jbspin.2017.10.003","article-title":"Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance.","volume":"85","author":"Scherlinger","year":"2018","journal-title":"Joint Bone Spine."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/art.40516","article-title":"Open-label, non-mandatory transitioning from originator etanercept to biosimilar SB4: six-month results from a controlled cohort study.","volume":"70","author":"Tweehuysen","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5152\/eurjrheum.2020.20080","article-title":"bDMARDs retention rate in the biosimilar era: a real-life monocentric study.","volume":"8","author":"Becciolini","year":"2021","journal-title":"Eur J Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9051528","article-title":"Actual persistence of abatacept in rheumatoid arthritis: results of the French-ric network.","volume":"9","author":"Salmon","year":"2020","journal-title":"J Clin Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative.","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B28","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of Spondyloarthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study.","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B30","doi-asserted-by":"publisher","first-page":"i28","DOI":"10.1136\/ard.59.suppl_1.i28","article-title":"Clinical outcome measures in rheumatoid arthritis.","volume":"59","author":"van Riel","year":"2000","journal-title":"Ann Rheum Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1136\/ard.2008.100826","article-title":"ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.","volume":"68","author":"van der Heijde","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105310","article-title":"Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: data from the ART-SFR Registry.","volume":"89","author":"Ruyssen-Witrand","year":"2022","journal-title":"Joint Bone Spine."},{"key":"B33","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1136\/medethics-2020-106306","article-title":"Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making.","volume":"46","author":"Aquino","year":"2020","journal-title":"J Med Ethics."},{"key":"B34","doi-asserted-by":"publisher","first-page":"795","DOI":"10.4314\/ejhs.v28i6.15","article-title":"Factors influencing prescribing decisions of physicians: a review.","volume":"28","author":"Davari","year":"1970","journal-title":"Ethiop J Health Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1345\/aph.1D390","article-title":"Factors that influence prescribing decisions.","volume":"38","author":"Schumock","year":"2004","journal-title":"Ann Pharmacother."},{"key":"B36","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40259-017-0244-3","article-title":"Perception of originator biologics and biosimilars: a survey among belgian rheumatoid arthritis patients and rheumatologists.","volume":"31","author":"van Overbeeke","year":"2017","journal-title":"BioDrugs."},{"key":"B37","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jsps.2021.10.012","article-title":"Perception of biosimilar biologics and non-medical prescription switching among rheumatologists: a saudi society for rheumatology initiative.","volume":"30","author":"Omair","year":"2022","journal-title":"Saudi Pharm J."},{"key":"B38","first-page":"S9","article-title":"Likelihood of use and perception towards biosimilars in rheumatoid arthritis: a global survey of rheumatologists.","volume":"34","author":"Narayanan","year":"2016","journal-title":"Clin Exp Rheumatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/PPA.S129333","article-title":"Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany.","volume":"11","author":"Waller","year":"2017","journal-title":"Patient Prefer Adherence."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.rhum.2020.10.179","article-title":"Les biosimilaires des anti-TNF?: les connaissances et croyances des rhumatologues fran\u00e7ais influencent leur prescription.","volume":"87","author":"Gervais","year":"2020","journal-title":"Rev Rhum."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12030335","article-title":"Adalimumab and ABP 501 in the treatment of a large cohort of patients with inflammatory arthritis: a real life retrospective analysis.","volume":"12","author":"Becciolini","year":"2022","journal-title":"J Pers Med."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105193","article-title":"Comparative persistence of the TNF antagonists in rheumatoid arthritis \u2013 a population-based cohort study.","volume":"9","author":"Fisher","year":"2014","journal-title":"PLoS One."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1111\/1756-185X.13375","article-title":"Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).","volume":"21","author":"Soubrier","year":"2018","journal-title":"Int J Rheum Dis."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa-2018-0101","article-title":"Medication persistence for psoriatic arthritis in a Brazilian real-world setting.","volume":"5","author":"Ribeiro da Silva","year":"2019","journal-title":"Future Sci OA."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2021-219951","article-title":"Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.","volume":"80","author":"Nabi","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/1756-185X.13243","article-title":"A retrospective review of the persistence on BDMARD s prescribed for the treatment of rheumatoid arthritis in the Australian population.","volume":"21","author":"Jones","year":"2018","journal-title":"Int J Rheum Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1136\/annrheumdis-2011-150573","article-title":"A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry.","volume":"71","author":"Greenberg","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194130","article-title":"Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study-.","volume":"13","author":"Ebina","year":"2018","journal-title":"PLoS One."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish Nationwide DANBIO Registry.","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","article-title":"Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry.","volume":"72","author":"Glintborg","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s40259-020-00442-x","article-title":"Drug survival of biologics in treating ankylosing spondylitis: a systematic review and meta-analysis of real-world evidence.","volume":"34","author":"Yu","year":"2020","journal-title":"BioDrugs."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-021-02417-x","article-title":"Treatment persistence of biologics among patients with psoriatic arthritis.","volume":"23","author":"Haddad","year":"2021","journal-title":"Arthritis Res Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0738-3991(03)00023-5","article-title":"How do patients with rheumatic disease experience their relationship with their doctors?","volume":"52","author":"Haugli","year":"2004","journal-title":"Patient Educ Couns."},{"key":"B54","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00296-018-4016-2","article-title":"Physician\u2013patient communication in rheumatology: a systematic review.","volume":"38","author":"Georgopoulou","year":"2018","journal-title":"Rheumatol Int."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.708168","article-title":"Real-Life retention rates and reasons for switching of biological DMARDs in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.","volume":"8","author":"Bhushan","year":"2021","journal-title":"Front Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3899\/jrheum.170477","article-title":"Comparative analysis and predictors of 10-year tumor necrosis factor inhibitors drug survival in patients with spondyloarthritis: first-year response predicts longterm drug persistence.","volume":"45","author":"Flouri","year":"2018","journal-title":"J Rheumatol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.3899\/jrheum.201549","article-title":"Comparison of men and women with axial spondyloarthritis in the us-based corrona psoriatic arthritis\/spondyloarthritis registry.","volume":"48","author":"Mease","year":"2021","journal-title":"J Rheumatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti\u2013tumor necrosis factor \u03b1 drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum."},{"key":"B59","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/039139889802100612","article-title":"Pain perception following subcutaneous injections of citrate-buffered and phosphate-buffered epoetin alpha.","volume":"21","author":"Yu","year":"1998","journal-title":"Int J Artif Organs."},{"key":"B60","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1742-7843.2006.pto_271.x","article-title":"Pain perception after subcutaneous injections of media containing different buffers.","volume":"98","author":"Laursen","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4103\/injr.injr_154_18","article-title":"Reduced injection site pain with succinate buffer-based adalimumab biosimilar (ZRC-3197) Injection (SUFFER Study): an observational study.","volume":"14","author":"Gharia","year":"2019","journal-title":"Indian J Rheumatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40744-020-00256-x","article-title":"Evaluation of adherence and persistence differences between adalimumab citrate-free and citrate formulations for patients with immune-mediated diseases in the United States.","volume":"8","author":"Bergman","year":"2021","journal-title":"Rheumatol Ther."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/kev019","article-title":"Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.","volume":"54","author":"Gabay","year":"2015","journal-title":"Rheumatology."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-021-01013-3","article-title":"Comparative efficacy and safety of adalimumab biosimilars and adalimumab in patients with rheumatoid arthritis presenting an insufficient response to methotrexate: a network meta-analysis.","author":"Lee","year":"2021","journal-title":"Z F\u00fcr Rheumatol."},{"key":"B65","first-page":"344","article-title":"Efficacy and safety of biosimilar and originator etanercept in rheumatoid arthritis patients: real-life data.","volume":"23","author":"Atzeni","year":"2021","journal-title":"Isr Med Assoc J IMAJ."},{"key":"B66","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.biologicals.2019.10.009","article-title":"Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis \u2013 A comparison in a real-world national cohort.","volume":"62","author":"Codreanu","year":"2019","journal-title":"Biologicals."},{"key":"B67","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s10067-020-05199-w","article-title":"Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.","volume":"40","author":"Bruni","year":"2021","journal-title":"Clin Rheumatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"S173","DOI":"10.1097\/RHU.0000000000001616","article-title":"Efficacy, safety, and immunogenicity of biosimilar etanercept (Enerceptan) versus its original form in combination with methotrexate in patients with rheumatoid arthritis: a randomized, multicenter, evaluator-blinded, noninferiority study.","volume":"27","author":"Strusberg","year":"2021","journal-title":"JCR J Clin Rheumatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/6107217","article-title":"The use of rheumatic disease comorbidity index for predicting clinical response and retention rate in a cohort of rheumatoid arthritis patients receiving tumor necrosis factor alpha inhibitors.","volume":"2019","author":"Biggioggero","year":"2019","journal-title":"BioMed Res Int."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90442-w","article-title":"Clinical factors associated with discontinuation of ts\/bDMARDs in rheumatic patients from the BIOBADASER III registry.","volume":"11","author":"Prior-Espa\u00f1ol","year":"2021","journal-title":"Sci Rep."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030621","article-title":"Efficacy and drug survival after switching from etanercept to the biosimilar SB4: a real-life long-term study.","volume":"11","author":"Parisi","year":"2022","journal-title":"J Clin Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.989514\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T12:37:10Z","timestamp":1665059830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.989514\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":71,"alternative-id":["10.3389\/fmed.2022.989514"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.989514","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"article-number":"989514"}}